Please assess the completion status of the following clinical trial:

Trial Title: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmation of metastatic or unresectable melanoma~* Melanoma must be documented to contain a BRAF V600 mutation by a CLIA approved assay~* Measurable disease~* Less than or equal to 2 prior systemic treatment regimens for distant metastatic disease~Exclusion Criteria:~* Pregnant or breastfeeding~* Chemotherapy or radiation therapy within 4 weeks~* Prior therapy with a BRAF inhibitor or MEK inhibitor or leflunomide~* Receiving other study agents~* Known brain metastases that are symptomatic and require corticosteroids~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib or leflunomide~* Uncontrolled intercurrent illness~* HIV-positive~* History of a different malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Leflunomide + Vemurafenib

Based on this trial design, predict the completion outcome and termination type (if applicable).